Peer review statement
Copyright
Conflict of Interest Statement
Manuscript presentation
Authorship
Publication categories
All correspondence, including notification of the Editor's decision and requests for revisions, will be by e-mail. All manuscript submissions should be made online at the Therapeutic Advances in Cardiovascular Disease SAGETRACK website: http://mc.manuscriptcentral.com/tak
Please contact Dan.Huke@sagepub.co.uk for further queries or if you have technical problems.
If you have not used the site before, please click the 'Create account' link and follow the on-screen instructions.If you have previously used the Therapeutic Advances in Cardiovascular Disease site, either as an author or a referee, please use your existing login details. If you do not know your login details, simply enter your email address in the "Forgot your password?" box and you will receive instructions on how to log in right away.Once you have logged in to the site, please select 'Author Center'.If you are submitting an invited paper, do NOT select 'Click here to submit a new manuscript'. Please click the 'Invited Manuscripts' link, then click the icon beside the manuscript title to complete the submission.
If your manuscript is unsolicited, please click the 'Click here to submit a new manuscript' link and follow the instructions.
If you do not wish to complete the manuscript submission process immediately, you may stop at any stage and return later. SAGETRACK will save your progress and any information you have entered. You may return to the site, log in again, and complete the submission at any point in the future.
Publication statement
Papers submitted to this Journal for publication are considered on condition that they have been neither submitted elsewhere, nor published elsewhere other than in abstract form. The Editors do not enter into correspondence about papers considered unsuitable for publication; their decision is final.
Requirements for publication in the Journal are in accordance with the International Committee of Medical Journal Editors' Uniform Requirements for Manuscripts Submitted to Biomedical Journals1
Peer review statement
Therapeutic Advances in Cardiovascular Disease strongly endorses the value and importance of peer review in scholarly journals publishing. All original research and review articles submitted to the Journal will be subject to comment and external review by no less than two reviewers adhering to a single blind peer review process in which the reviewer's name is routinely withheld from the author unless the reviewer(s) requests a preference for their identity to be revealed. Manuscripts are reviewed as rapidly as possible, and a first editorial decision is generally reached within 2-3 weeks of submission. Authors are requested to suggest the names, affiliations and contact information of up to six individuals who may be suitable to serve as referees, but the Editors are under no obligation to use all or any of these individuals as reviewers. Manuscripts are reviewed initially by the Editors and only those papers that meet the scientific and editorial standards of the Journal, and fit within the aims and scope of the Journal, will be sent for outside review.
Conflict of Interest Statement
As most, if not all responsible adults in professional positions have potential conflicts of interest, the Journal has decided to instigate the following policy. By conflicts of interest we mean relationships, allegiances or hostilities to particular groups, organizations or interests, which may influence excessively one's judgements or actions. The issue is particularly sensitive when such interests are private and/or may result in personal gain.
Our expectation is that authors will always endeavour to recognize such interests and to act independently when giving their opinions or presenting data. However, it is also now essential that they are seen to acknowledge potential risks, especially where these might be interpreted to their discredit and to the discredit of the Journal.
To this end, we encourage authors to disclose what potential conflicts of interest they have. However, the Journal can accept no responsibility for omissions or lack of clarity - this must rest with the author.
As guidance, the risks that should be addressed lie in particular areas:
1. Where individuals have patents or inventions from which they may derive personal benefit in the area of cardiovascular disease.
2. Where there is ownership or part ownership of a company with interests in the area of cardiovascular disease. This would include holding the shares of major companies in one's own name, or those of dependent family members.
3. Accepting a personal retainer from any company with an interest in cardiovascular disease.
4. Acting as a consultant to any company with an interest in cardiovascular disease.
5. Acting as an expert witness, either friendly or hostile to any company with an interest in cardiovascular disease.
6. Holding a research grant from any company with an interest in cardiovascular disease.
7. Membership of the speakers' bureau for any company.
8. The acceptance of paid speaking engagements in industry supported symposia.
9. The acceptance of travel or hospitality not related to a speaking engagement.
Related concerns are appropriate if the relationships implied under any of items 3–9 also exist in respect of a relationship to a voluntary organization, a charity, a law firm, a department of government, an investment company or any other formally constituted body with interests in the field of cardiovascular disease.
It is not expected that the details of financial arrangements should be disclosed.
Authorship
Authors should declare whether or not they had assistance with study design, data collection, data analysis, or manuscript preparation. If such assistance was available, the authors should disclose the identity of the people that provided this assistance and the entity that supported it in the published article. Financial and material support should also be acknowledged.
Publication categories
The Journal considers the following kinds of article for publication:
1. Research Reports, describing new experimental findings;
2. Review Articles. The Editors wish to encourage the following types of review, but request that authors contact them in advance:
(a) general reviews that provide a synthesis of an area of Therapeutic Advances in Cardiovascular Disease;
(b) perspectives - brief overviews, which are 4-6 printed pages in length including references, that address important new areas of general interest;
(c) critiques - focused and provocative reviews that are followed by a number of invited commentaries, with a concluding reply from the main author;
(d) structured case reports - outlining an interesting case, including a section on "implications for clinical care" (prevention, recognition and management);
3. Letters to the Editor
These should be as concise as possible and never exceed 500 words
Manuscript presentation
Therapeutic Advances in Cardiovascular Disease subscribes predominantly to the editorial preferences expressed in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals issued by the International Committee of Medical Journal Editors.
Each page should be numbered and identified with a shortened version of the title.
Elements within the Manuscript
Abstract
The abstract should accurately and concisely reflect the content of the article. Original research articles should include structured abstracts, using the headings Objective, Methods, Results, and Conclusions.
Key words
(or key word phrases) 2-8 to accompany the abstract. They should, if possible, be drawn from the MeSH list of Index Medicus and be chosen with a view to useful cross-indexing of the article.
Main text
Subdivide your article with appropriate headings. Use no more than two levels of subheading.
Acknowledgements
Between the end of the main text and the start of the references section, please acknowledge sources of financial and material support, and those who have contributed intellectually, with their consent.
References
EndNote Users: Click here to download the journal's style file.
In the main text, place each author in square parentheses, throughout the text, tables, and legends:
[Author 1, 2004]
[Author 1 and Author 2, 2006]
[Author et al. 2007]
In the reference list, all references appear alphabetically. Please list up to 6 authors, or 6 authors followed by "et al."
Authors: List each author's last name and initials; full first names are not included. For books with chapters written by individual authors, list the authors of the chapter first, then the chapter title, followed by "In", the editors' names, and the book title, the publisher, and the location.
Book titles, chapter titles: Capitalize the first letter of the first word in the title. The rest of the title is in lower-case, with the exception of proper names (see example 3 below). Do not underline the title; do not use italics.
Journal citations in the reference list: Abduljawad, K.A.J. and Langley, R.W. (2001) Article title here. J Psychopharmacol 15: 237–242.Smith, H., Miller, M., Agarwal, S., Sinetti, M., Yan, C., Long, T. et al. (2000) Article title here. J Psychopharmacol 15: 237–242.
Book citation in the reference list: Lader, M. (1977) Effects of psychotropic drugs on auditory evoked potentials in man. In Desmedt, J.E. (ed), Auditory evoked potentials in man: psychopharmacology correlates of evoked potentials, Karger: Basel.Tables
Tables must all be cited in the text, carry brief but complete titles, and be numbered consecutively with Arabic numerals. Keep rules (horizontal only) to a minimum.
Figures
Figures should be supplied as vector-based, separate .eps files (not as .tiff files, and not only inserted in the Word or pdf file), with a resolution of 300dpi (dots per inch). They should be used with discretion to clarify (not duplicate) the text. They should be cited in the text, using arabic numerals, and their approximate location in the paper clearly indicated [Figure 1 near here]. They should, for preference, be supplied at reproduction size (single- or double-column width), and lettering should be no smaller than 8pt type.
Legends should be explanatory but succinct. They should carry the arabic numerals applicable to the figures, and be provided as a separate typed (double-spaced) list at the end of the paper, along with the figures themselves.
Elements of Overall Manuscript Style
Units of measurement
Express these in SI and metric units; older conventional units may be added in parentheses. Nomenclature: Use the generic or chemical name of any drug, in lower case; the specific trade name (capitalized) may be given in parentheses after the first text reference.
Abbreviations and symbols
Use standard abbreviations, and define them in full in the first instance unless they are standard units of measurement. Avoid any use of abbreviations in the article title and abstract.
Ethics
When reporting experiments on human subjects, indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) or with the Declaration of Helsinki 1975, revised Hong Kong 1989. Do not use patients' names, initials or hospital numbers, especially in illustrative material. When reporting experiments on animals, indicate whether the institution's or the National Research Council's guide for, or any national law on, the care and use of laboratory animals was followed.
Permissions
Authors must obtain written permission from the copyright holder (original author or publisher) to include in their paper any previously published material. Credit should follow the style and location requested by the copyright holder.
On Publication
Access to 25 free e-prints will be provided; the corresponding author will receive one complimentary copy of the journal for each contributor.
_______________________________________
1 International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication http://www.icmje.org/. Updated October 2007. Retrieved April 2008
